U-Protein Express Overview

  • Founded
  • 2007
Founded
  • Status
  • Acquired/​Merged
  • Employees
  • 4
Employees
  • Latest Deal Type
  • M&A
  • Latest Deal Amount
  • $8.04M
Latest Deal Amount

U-Protein Express General Information

Description

Operator of a contract research platform intended to focus on recombinant protein production. The company's contract research platform offers fast and large-scale production of (mammalian) recombinant proteins and antibodies for research and pre-clinical applications as well as produces and purifies recombinant proteins and antibodies via its r-PEx transient expression platform, providing customers with custom antibody engineering and production services to support their research and development efforts.

Contact Information

Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Drug Discovery
Parent Company
Primary Office
  • Utrecht Science Park
  • Yalelaan 62
  • 3584 CM Utrecht
  • Netherlands
+31 030 000 0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

U-Protein Express Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Merger/Acquisition 23-Aug-2017 $8.04M 00.000 Completed Generating Revenue
2. Grant 31-Mar-2015 Completed Generating Revenue
1. Early Stage VC Completed Startup
To view U-Protein Express’s complete valuation and funding history, request access »

U-Protein Express Patents

U-Protein Express Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20160333074-A1 Novel polypeptide and uses thereof Abandoned 17-Oct-2013 0000000000 0
CA-2927428-A1 Novel polypeptide and uses thereof Abandoned 17-Oct-2013 0000000000
EP-3057607-A1 Novel polypeptide and uses thereof. Withdrawn 17-Oct-2013 0000000000
US-20110165620-A1 Method for the production of proteins or protein fragments Abandoned 28-May-2008 000000000 0
AU-2008356942-A1 Method for the production of proteins or protein fragments Abandoned 28-May-2008 C12N15/85

U-Protein Express Executive Team (3)

Name Title Board Seat Contact Info
Martin Hessing Ph.D Co-Founder & Chief Executive Officer
Wieger Hemrika Ph.D Chief Operating Officer & Co-Founder
Roland Romijn Ph.D Chief Scientific Officer & Co-Founder
To view U-Protein Express’s complete executive team members history, request access »

U-Protein Express Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

U-Protein Express Former Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
IPC-BioFarmind Other 000 0000 000000 0
Nederlandse Organisatie voor Wetenschappelijk Onderzoek Government 000 0000 000000 0
Utrecht Holdings Venture Capital Minority 000 0000 000000 0
To view U-Protein Express’s complete investors history, request access »